PanDrugs suggests Navitoclax since CDK6 is a biomarker of Navitoclax response and BCL2 as pathway member because it is downstream to the TP53 and ERBB2 genes which are altered in this particular NSCLC patient. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.